hotspot -WSS

hotspot

author：entertainment 2025-08-12 09:12:55 - browse：4488

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Covid silver lining: Unprecedented look at human immune system

focus

WSS

Bird flu in dairy cattle: New measures to control spread to humans

Study: Black kids more likely to die after surgery than white kids

Bird flu reported in person exposed to presumably infected cattle

Scientists uncover potential path to treating deadly childhood tumor

Let's speed up science by embracing open access publishing

Researchers test human milk's ability to repair gut microbiome

leisure time

hotspot

entertainment

Peter Hotez and the public health issue of online harassment

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Malaria cases in Florida and Texas: Here’s what you need to know

Researchers test human milk's ability to repair gut microbiome

Jerome Adams on the need for new antivirals for Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bird flu reported in person exposed to presumably infected cattle

entertainment

ASCO: AstraZeneca says CAR

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Bird flu in dairy cattle: New measures to control spread to humans

How to increase colonoscopy rates? Looks like an AI can help

focus

Wikipedia

focus

knowledge